seekingalpha.com
electroCore, Inc. (ECOR) Q4 2025 Earnings Call Transcript
electroCore, Inc. (ECOR) Q4 2025 Earnings Call Transcript
electroCore, Inc.ECORNASDAQ
Loading
Latest News
Loading news...
zacks.com
electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
electroCore, Inc. (ECOR) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.4 per share a year ago.
globenewswire.com
electroCore Announces Full Year 2025 Financial Results and Organizational Changes
Record f ull year 2025 net sales of $ 32.0 , an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales
proactiveinvestors.co.uk
Ecora Royalties emerges as defensive commodity play as Iran conflict roils mining sector
The royalty company's structure shields investors from rising fuel and chemical costs that are squeezing conventional miners RBC Capital Markets has highlighted Ecora Royalties PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF, FRA:HGR), the London-listed mining royalty company, as one of the better-performing equities since the outbreak of war with Iran. The Canadian bank reiterated its 'outperform' rating and 175p price target against a current share price of 133p (up 3%).
globenewswire.com
electroCore to Participate at the 38th Annual Roth Conference
ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual Roth Conference March 22-24 at the Ritz-Carlton in Laguna Niguel, California.
globenewswire.com
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026
ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and full year ended December 31, 2025, after the close of the market on Thursday, March 19, 2026.
zacks.com
electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
electroCore (ECOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
proactiveinvestors.co.uk
Ecora Royalties hits inflexion point as base metals revenue surges 150%; shares up 140% in a year
Critical minerals now account for 63% of portfolio contribution as the royalty company's pivot away from coal produces tangible results Ecora Royalties PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF, FRA:HGR) has consciously positioned itself away from steelmaking coal dependence. In 2025, that bet paid off.
proactiveinvestors.co.uk
Ecora Royalties says "stellar performance" marks inflection point for its portfolio
Ecora Royalties PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF, FRA:HGR) has, in today's trading update for the fourth quarter, reported a total portfolio contribution of $57 million for the year ended 31 December. The group noted that the Q4 portfolio contribution amounted to $14.3 million.
globenewswire.com
Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore's gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)
ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™ Sapphire, electroCore's non-invasive vagus nerve stimulator (nVNS), can be used as an adjunctive treatment of symptoms associated with PTSD.
globenewswire.com
electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million
ROCKAWAY, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today provided select unaudited preliminary financial guidance for the full year and fourth quarter of 2025.
defenseworld.net
Financial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR)
electroCore (NASDAQ: ECOR - Get Free Report) and Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. Earnings and Valuation This table compares electroCore and
defenseworld.net
electroCore (NASDAQ:ECOR) Trading Up 1.4% – What’s Next?
Shares of electroCore, Inc. (NASDAQ: ECOR - Get Free Report) traded up 1.4% on Friday. The stock traded as high as $4.96 and last traded at $4.95. 19,108 shares were traded during mid-day trading, a decline of 46% from the average session volume of 35,493 shares. The stock had previously closed at $4.88. Wall Street
seekingalpha.com
electroCore, Inc. (ECOR) Discusses Neuromodulation Platform, Business Evolution, and Strategic Priorities Transcript
electroCore, Inc. (ECOR) Discusses Neuromodulation Platform, Business Evolution, and Strategic Priorities Transcript
globenewswire.com
TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen
ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced the publication of a peer reviewed paper titled “Non-Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High-Stress Military Training Environment” which will be presented at the Applied Human Factors and Ergonomics (AHFE2025) Conference on December 8, 2025.
proactiveinvestors.co.uk
Ecora Resources boosted by 'best' drill results yet at Patterson Corridor East uranium project
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) has reported new assay results from operator NexGen Energy showing the highest-grade mineralisation so far at the Patterson Corridor East uranium project in Canada. The royalties-focused investor said these results represent the strongest reported grades to date from the project - and directed investors to the full NexGen announcement for further technical information.
globenewswire.com
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum.
seekingalpha.com
electroCore, Inc. (ECOR) Q3 2025 Earnings Call Transcript
electroCore, Inc. ( ECOR ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Daniel Goldberger - CEO & Director Thomas Errico - Founder & Independent Chairman Joshua Lev - Chief Financial Officer Conference Call Participants Rob Fink - FNK IR LLC Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Jeremy Pearlman - Maxim Group LLC, Research Division Walter Schenker - MAZ Capital Advisors, LLC Presentation Rob Fink FNK IR LLC Greetings, everyone, and welcome to the electroCore Third Quarter 2025 Earnings Conference Call.
zacks.com
electroCore, Inc. (ECOR) Reports Q3 Loss, Beats Revenue Estimates
electroCore, Inc. (ECOR) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.31 per share a year ago.
globenewswire.com
electroCore Announces Third Quarter 2025 Financial Results
Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024